These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37549775)

  • 21. Low Dose Buprenorphine Induction With Full Agonist Overlap in Hospitalized Patients With Opioid Use Disorder: A Retrospective Cohort Study.
    Bhatraju EP; Klein JW; Hall AN; Chen DR; Iles-Shih M; Tsui JI; Merrill JO
    J Addict Med; 2022 Jul-Aug 01; 16(4):461-465. PubMed ID: 34954743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beyond harm-producing versus harm-reducing: A qualitative meta-synthesis of people who use drugs' perspectives of and experiences with the extramedical use and diversion of buprenorphine.
    Sud A; Salamanca-Buentello F; Buchman DZ; Sabioni P; Majid U
    J Subst Abuse Treat; 2022 Apr; 135():108651. PubMed ID: 34728134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
    Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
    J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multimodal Treatment Options, Including Rotating to Buprenorphine, Within a Multidisciplinary Pain Clinic for Patients on Risky Opioid Regimens: A Quality Improvement Study.
    Oldfield BJ; Edens EL; Agnoli A; Bone CW; Cervone DJ; Edmond SN; Manhapra A; Sellinger JJ; Becker WC
    Pain Med; 2018 Sep; 19(suppl_1):S38-S45. PubMed ID: 30203007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale and design of a multisite randomized clinical trial examining an integrated behavioral treatment for veterans with co-occurring chronic pain and opioid use disorder: The pain and opioids integrated treatment in veterans (POSITIVE) trial.
    Vowles KE; Witkiewitz K; Clarke E; Schmidt Z; Borsari B; Edwards KE; Korecki JR; Moniz-Lewis DI; Bondzie JA; Mullins C; Thoreson CI; Delacruz J; Wilkins CH; Nelson S; Delventura J; Henderson R; Katz A; Hua W; Watson E; Baxley C; Canlas BR; Pendleton T; Herbst E; Batki S
    Contemp Clin Trials; 2023 Mar; 126():107096. PubMed ID: 36693589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Complex Case of Kratom Dependence, Depression, and Chronic Pain in Opioid Use Disorder: Effects of Buprenorphine in Clinical Management.
    Bowe A; Kerr PL
    J Psychoactive Drugs; 2020; 52(5):447-452. PubMed ID: 32546067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients.
    Daitch D; Daitch J; Novinson D; Frey M; Mitnick C; Pergolizzi J
    Pain Med; 2014 Dec; 15(12):2087-94. PubMed ID: 25220043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementation of a collaborative care management program with buprenorphine in primary care: a comparison between opioid-dependent patients and patients with chronic pain using opioids nonmedically.
    Suzuki J; Matthews ML; Brick D; Nguyen MT; Wasan AD; Jamison RN; Ellner AL; Tishler LW; Weiss RD
    J Opioid Manag; 2014; 10(3):159-68. PubMed ID: 24944066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microinduction to Buprenorphine from Methadone for Chronic Pain: Outpatient Protocol with Case Examples.
    Jasmine Silva M; Coffee Z; Goza J; Rumrill K
    J Pain Palliat Care Pharmacother; 2022 Mar; 36(1):40-48. PubMed ID: 35290161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association Between Pain Intensity and Discontinuing Opioid Therapy or Transitioning to Intermittent Opioid Therapy After Initial Long-Term Opioid Therapy: A Retrospective Cohort Study.
    Hayes CJ; Krebs EE; Brown J; Li C; Hudson T; Martin BC
    J Pain; 2021 Dec; 22(12):1709-1721. PubMed ID: 34186177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Micro-dosing Intravenous Buprenorphine to Rapidly Transition From Full Opioid Agonists.
    Thakrar AP; Jablonski L; Ratner J; Rastegar DA
    J Addict Med; 2022 Jan-Feb 01; 16(1):122-124. PubMed ID: 33758112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion.
    Webster L; Gudin J; Raffa RB; Kuchera J; Rauck R; Fudin J; Adler J; Mallick-Searle T
    Pain Med; 2020 Apr; 21(4):714-723. PubMed ID: 31917418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rethinking Opioid Dose Tapering, Prescription Opioid Dependence, and Indications for Buprenorphine.
    Chou R; Ballantyne J; Lembke A
    Ann Intern Med; 2019 Sep; 171(6):427-429. PubMed ID: 31450240
    [No Abstract]   [Full Text] [Related]  

  • 34. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transdermal buprenorphine for in-hospital transition from full agonist opioids to sublingual buprenorphine: a retrospective observational cohort study.
    Baumgartner K; Salmo E; Liss D; Devgun J; Mullins M; Galati B; Kelly J; Schwarz E
    Clin Toxicol (Phila); 2022 Jun; 60(6):688-693. PubMed ID: 35048759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "I'm Not Gonna Pull the Rug out From Under You": Patient-Provider Communication About Opioid Tapering.
    Matthias MS; Johnson NL; Shields CG; Bair MJ; MacKie P; Huffman M; Alexander SC
    J Pain; 2017 Nov; 18(11):1365-1373. PubMed ID: 28690000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized clinical trial comparing buprenorphine/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction.
    Neumann AM; Blondell RD; Hoopsick RA; Homish GG
    J Addict Dis; 2020; 38(1):33-41. PubMed ID: 31774028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.
    Rosenblum A; Cruciani RA; Strain EC; Cleland CM; Joseph H; Magura S; Marsch LA; McNicholas LF; Savage SR; Sundaram A; Portenoy RK
    J Opioid Manag; 2012; 8(6):369-82. PubMed ID: 23264315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary care management of Long-Term opioid therapy.
    Coffin PO; Martinez RS; Wylie B; Ryder B
    Ann Med; 2022 Dec; 54(1):2451-2469. PubMed ID: 36111417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial.
    Ellerbroek H; van den Heuvel SAS; Dahan A; Timmerman H; Kramers C; Schellekens AFA
    Addict Sci Clin Pract; 2022 Sep; 17(1):47. PubMed ID: 36057608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.